Company NFL Biosciences

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-15 EDT			5-day change	1st Jan Change
0.8500 ^EUR	-0.12%		-3.19%	-27.84%

07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
06-30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI

Business description: NFL Biosciences

NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.

At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Number of employees: 4

Sales by Activity: NFL Biosciences

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Biotechnology (Startups)	39	22	200K	46	188

See all business segments

Geographical breakdown of sales: NFL Biosciences

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
France	39	22	200K	46	188

See all geographic segments

Executive Committee: NFL Biosciences

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-
Ignacio Faus CEO	Chief Executive Officer	-	2021-05-18
Lara Babich PRN	Corporate Officer/Principal	-	2023-12-31

See NFL BIOSCIENCES governance

Composition of the Board of Directors: NFL Biosciences

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16
Francis Ahner BRD	Director/Board Member	-	2021-05-18
Yannick Plétan BRD	Director/Board Member	-	2021-05-18
Dominique Côté BRD	Director/Board Member	-	2023-05-31

Composition of the Board of Directors

Shareholders: NFL Biosciences

Name	Stocks	%	Valuation
Friedland Gestion SAS 0.1609 %	20,395	0.1609 %	20 286 €

List of NFL BIOSCIENCES shareholders

Company details: NFL Biosciences

NFL Biosciences SAS

199 rue Hélène Boucher

34170, Castelnau-le-Lez

+33 4 11 93 76 67

http://www.nflbiosciences.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-0.12%	-3.19%	-25.44%	-67.92%	12.34M
ARGENX SE	-1.39%	-7.58%	+54.00%	+124.73%	54.49B
WUXI APPTEC CO., LTD.	+3.13%	+11.16%	+67.30%	+94.35%	55.93B
INSMED INCORPORATED	-0.27%	-2.69%	+7.77%	+433.06%	23.87B
BIONTECH SE	+1.76%	-2.44%	-17.13%	-15.01%	22.86B
WUXI BIOLOGICS (CAYMAN) INC.	+3.51%	+7.50%	+47.81%	-3.33%	20B
GENMAB A/S	+1.94%	-0.03%	+38.19%	-27.77%	17.48B
PHARMAESSENTIA CORPORATION	+10.00%	-2.06%	+210.10%	+370.99%	15.39B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.69%	+4.38%	+56.51%	+712.88%	15.19B
EXELIXIS, INC.	-0.39%	-2.68%	+21.87%	+186.49%	14.02B
Average	+2.59%	-0.00%	+46.10%	+180.85%	23.92B
Weighted average by Cap.	+2.10%	+0.47%	+52.35%	+169.99%